Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Glucagon-like peptide 1 receptor agonists (GLP-1s) are on track to become one of the largest drug classes in history, driven by demand for weight loss alternatives and the potential of GLP-1s to treat a range of conditions such as diabetes, cardiovascular risk, liver disease, and dementia
saludos :) P: Hola
You may very well be and have no idea
DJD was supported in part by a Canada Research Chair in Regulatory Peptides, a Canada Research Chair in Regulatory Peptides in Incretin Biology, and operating grant 123391 from the Canadian Institutes of Health Research
Model building Models were built into cryo-EM density using a combination of coot v 0.9.8.94 and the ISOLDE v 1.6 plugin in ChimeraX v 1.9
Here, we have compared the glucagonostatic effects of GLP-1(736) and (936) in vitro using physiological (pmol/l) concentrations of the peptides and over a wider range of glucose concentrations in isolated mouse and human islets (some from donors with type 2 diabetes) and extend these data to the in vivo situation with a particular focus on the counterregulatory increase in plasma glucagon during insulin-induced hypoglycaemia
US$ 28.73
US$ 22.95
US$ 27.27
US$ 23.16
US$ 23.87
